Baudax Bio shares rocket as lead clinical candidate gains FDA orphan drug designationProactive Investors • 09/28/23
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with InhibitorsGlobeNewsWire • 09/28/23
Here's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 09/18/23
Baudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/07/23
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common StockGlobeNewsWire • 08/23/23
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 08/17/23
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/16/23
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000GlobeNewsWire • 06/07/23
Baudax Bio Reports First Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/23
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 TrialGlobeNewsWire • 04/24/23
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business UpdateGlobeNewsWire • 02/23/23